ABEO Earnings Date: Nov 11, 2026 (Estimated) — Abeona Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ABEO's next earnings date?
Abeona Therapeutics Inc. (ABEO) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.14 on revenue of $14.8M.
How did ABEO do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Abeona Therapeutics Inc. posted EPS of -$0.35 versus the -$0.23 estimate, a miss of 45.8%. Revenue was $11.4M against a $12.2M estimate. The stock's 1-day post-earnings move was -14.9%.
How much does ABEO stock move after earnings?
ABEO beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.9% (up or down) in the day after earnings.
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.23 | -0.35 | -45.83% | $11.4M | ❌ Miss | -14.95% | -17.83% | -27.41% |
| 2026-05-13 | Q1 2026 | -0.38 | -0.30 | +21.05% | $8.7M | ✅ Beat | +0.53% | -9.86% | -2.64% |
| 2026-03-17 | Q4 2025 | -0.36 | -0.34 | +5.56% | $5.4M | ✅ Beat | -3.84% | -10.71% | +9.09% |
| 2025-11-12 | Q3 2025 | -0.31 | -0.10 | +67.74% | $0 | ✅ Beat | +18.47% | +7.43% | +32.37% |
| 2025-08-14 | Q2 2025 | -0.39 | 1.71 | +538.46% | $0 | ✅ Beat | +10.21% | +6.71% | -1.98% |
| 2025-03-20 | Q4 2024 | -0.34 | -0.14 | +58.82% | $0 | ✅ Beat | -1.15% | -4.04% | -6.92% |
| 2024-11-14 | Q3 2024 | -0.40 | -0.63 | -57.50% | $0 | ❌ Miss | -2.46% | -5.74% | -3.44% |
| 2024-08-12 | Q2 2024 | -0.36 | -0.26 | +27.78% | $0 | ✅ Beat | +11.99% | +13.12% | +25.79% |
Showing last 8 quarters.